Authorized purpose: Post-processing segmentation, quantification, and reporting of brain signal hyperintensities on T2w FLAIR and T1w post-contrast MRI; not detection or specific disease diagnosis.
Clinical role
Post-processing segmentation, quantification, and reporting support complementary to radiologist review.
Images and patients
MRI · Brain signal hyperintensities
Key limitation
Keep in mind: Not intended for detection or specific diagnosis of disease or for detection of signal hyperintensities. It must not replace full MRI evaluation or physician decisions. Contraindicated for pediatric patients and patients who have undergone brain tumor or other resection surgery.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Post-processing segmentation, quantification, and reporting of brain signal hyperintensities on T2w FLAIR and T1w post-contrast MRI; not detection or specific disease diagnosis.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain signal hyperintensities Input: DICOM T2w FLAIR and T1w post-contrast brain MR images from adults aged 21 and above; pediatric patients and patients after brain tumor or other resection surgery are contraindicated.
Who uses it?Intended users: Trained radiologists, imaging professionals, and other clinicians working with radiological images; trained technical personnel install the software.
What does the software produce?Output: DICOM Secondary Capture series with segmentation overlays and total hyperintensity volumes, a DICOM Encapsulated PDF report, and a DICOM SR summarizing volume measurements; outputs are intended for DICOM workstations and PACS.
What is its most important limitation?Key limitation: Not intended for detection or specific diagnosis of disease or for detection of signal hyperintensities. It must not replace full MRI evaluation or physician decisions. Contraindicated for pediatric patients and patients who have undergone brain tumor or other resection surgery.
Clinical takeaway. Clinical role: Post-processing segmentation, quantification, and reporting of brain signal hyperintensities on T2w FLAIR and T1w post-contrast MRI; not detection or specific disease diagnosis.
Evidence takeaway. Evidence from the reviewed source record: FDA performance testing compared software segmentations with a STAPLE consensus of three expert neuroradiologist segmentations. Contrast-enhancement validation used 131 cases from four hospital systems. The lower bound of the 95% CI for volume-measurement R2 was 0.94, the lower bound for DICE was 0.81, and reproducibility testing showed R2 of 0.92; the packet also reports size- and brightness-stratified R2/median-DICE results.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Post-processing segmentation, quantification, and reporting of brain signal hyperintensities on T2w FLAIR and T1w post-contrast MRI; not detection or specific disease diagnosis.
DICOM T2w FLAIR and T1w post-contrast brain MR images from adults aged 21 and above; pediatric patients and patients after brain tumor or other resection surgery are contraindicated.
DICOM Secondary Capture series with segmentation overlays and total hyperintensity volumes, a DICOM Encapsulated PDF report, and a DICOM SR summarizing volume measurements; outputs are intended for DICOM workstations and PACS.
Not intended for detection or specific diagnosis of disease or for detection of signal hyperintensities. It must not replace full MRI evaluation or physician decisions. Contraindicated for pediatric patients and patients who have undergone brain tumor or other resection surgery.
FDA performance testing compared software segmentations with a STAPLE consensus of three expert neuroradiologist segmentations. Contrast-enhancement validation used 131 cases from four hospital systems. The lower bound of the 95% CI for volume-measurement R2 was 0.94, the lower bound for DICE was 0.81, and reproducibility testing showed R2 of 0.92; the packet also reports size- and brightness-stratified R2/median-DICE results.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA performance testing compared software segmentations with a STAPLE consensus of three expert neuroradiologist segmentations. Contrast-enhancement validation used 131 cases from four hospital systems. The lower bound of the 95% CI for volume-measurement R2 was 0.94, the lower bound for DICE was 0.81, and reproducibility testing showed R2 of 0.92; the packet also reports size- and brightness-stratified R2/median-DICE results.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
GBrain MRI regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K252362
Samplen=131
Sites4
IndependenceIndependence not established
K252362
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K252362. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM T2w FLAIR and T1w post-contrast brain MR images from adults aged 21 and above; pediatric patients and patients after brain tumor or other resection surgery are contraindicated.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The device accepts DICOM input and produces DICOM output that can be displayed on most third-party DICOM workstations and PACS. It is packaged as a computing appliance with DICOM file transfer, does not require a user interface after installation, and reports processing errors in output series reports or system logs; exact local interfaces are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes GBrain MRI as packaged as a computing appliance supporting DICOM file transfer for input and output of results, installed by trained technical personnel and designed without the need for a user interface after installation. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "From a workflow perspective, GBrain MRI is packaged as a computing appliance that is capable of supporting DICOM file transfer for input, and output of results." … "The software is designed without the need for a user interface after installation.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: DICOM Secondary Capture series with segmentation overlays and total hyperintensity volumes, a DICOM Encapsulated PDF report, and a DICOM SR summarizing volume measurements; outputs are intended for DICOM workstations and PACS.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: DICOM Secondary Capture series with segmentation overlays and total hyperintensity volumes, a DICOM Encapsulated PDF report, and a DICOM SR summarizing volume measurements; outputs are intended for DICOM workstations and PACS.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes GBrain MRI as packaged as a computing appliance supporting DICOM file transfer for input and output of results, installed by trained technical personnel and designed without the need for a user interface after installation. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "From a workflow perspective, GBrain MRI is packaged as a computing appliance that is capable of supporting DICOM file transfer for input, and output of results." … "The software is designed without the need for a user interface after installation.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The device accepts DICOM input and produces DICOM output that can be displayed on most third-party DICOM workstations and PACS. It is packaged as a computing appliance with DICOM file transfer, does not require a user interface after installation, and reports processing errors in output series reports or system logs; exact local interfaces are not established.
ACR AI Central provides an exact-submission model card for GBrain MRI; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K252362 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Post-processing automatic segmentation, quantification, and reporting of brain FLAIR hyperintensity volumes to support structural MRI review; not disease detection or diagnosis.
Authorized purpose: MRCP+v1 is indicated for use as a software-based image processing system for non-invasive, quantitative assessment of biliary system structures by facilitating the generation, visualization and review of three-dimensional quantitative biliary system models and anatomical image data.MRCP+v1 calculates quantitative three-dimensional biliary system models that enable measurement of bile duct widths and automatic detection of regions of variation (ROV) of tubular structures. MRCP+v1 includes tools for interactive segmentation and labelling of the biliary system and tubular structures. MRCP+v1 allows for regional volumetric analysis of segmented tree-like, tubular structures and the gallbladder. Combining image viewing, processing and reporting tools, the metrics provided is designed to support physicians in the visualization, evaluation and reporting of hepatobiliary structures. These models and the physical parameters derived from the models, when interpreted by a trained physician, yield information that may assist in biliary systemassessment.MRCP+v1 is designed to utilize DICOM compliant MRCP datasets, acquired on supported MR scanners using supported MRCP acquisition protocols.MRCP+v1 is suitable for all patients not contra-indicated for MRI.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric data may be compared to reference percentile data.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.